Oragenics completes spray-dry manufacturing of ONP-002 for Phase IIa concussion trial

ORAGENICS INC

ONP-002 produced as spray-dried nanoparticle powder and filled in Oragenics' breath-propelled intranasal device.
Phase IIa trial to enroll 40 concussed patients (1:1 placebo/ONP-002), dosed twice daily for 5 days starting within 8 hours of injury in ED.
Trial will be conducted in Australia; patient-reported outcomes and blood biomarkers included in evaluation.
No approved pharmaceutical treatment for concussion; ONP-002 is a novel neurosteroid designed as first-in-class therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.